Gauss Surgical, Inc., a Los Altos, CA-based a medical technology company, closed $12.6m Series B financing.
The round was led by Providence Ventures, with participation from Jump Capital, and existing investors Promus Ventures, LifeForce Ventures, Summation Health Ventures, and the StanfordStartX Fund. In conjunction with the funding, Daniel Galles, a partner at Providence Ventures, and Mike Collett, founder and managing partner of Promus Ventures, will join Gauss’ board of directors. In addition, Dr. Garrett Vygantas, partner at Jump Capital, will join as Board Observer.
The company has raised $24.6m in total funding.
Led by founder and Chief Executive Officer Siddarth Satish, Gauss Surgical has developed Triton, a platform for real-time monitoring of surgical blood loss, which combines computer vision and machine learning applications, to support surgeons in making better decisions, armed with accurate blood loss assessments.
Triton, which has four FDA clearances along with approval for CE Mark, is in clinical use at several health systems in the United States including HackensackUMC, Cedars-Sinai Medical Center, the MemorialCare Health System, UC Irvine Medical Center, and others.